Podcast: Towards better health with Rarity
Speed of Life is a podcast series focusing on innovations accelerating towards better health, by STUNS Life Science. It’s sponsored through a project funded by European Regional Development Fund (ERDF), Region Uppsala and STUNS Life Science. Rarity Bioscience, was invited to share our story. Our CTO and founder Lei Chen and Linus Bosaeus, CEO, were […]
One year: Research, innovation and improved patient outcome
Rarity Bioscience was founded in July 2021 based on an innovation by Dr. Lei Chen and Professor Ulf Landegren. Linus Bosaeus was appointed as the CEO and shortly after, the seed round was raised. Since the start, the operational team has grown from two to eight employees and is still growing. Rarity celebrates one year […]
superRCA published in Nature Communications
With an innovative, super sensitive technology, so-called superRCA, remaining cancer cells can be detected after treatment of acute myeloid leukemia (AML). The method is presented in an article in Nature Communication. The technology, superRCA, tracks mutations with greater sensitivity than PCR-based technologies and can detect recurrence of cancer earlier. The technology is fast, sensitive, reliable […]
Raritys teknik är 10 till 100 gånger mer känslig än dagens teknik
Inte ens ett år gamla har Rarity Bioscience fått anslag från Swelife och Medtech4health. Nu hoppas Linus Bosaeus, vd på Rarity, att tekniken för detektion av mutationer i blodprov hos cancerpatienter ska nå laboratorier redan nästa år. “Vår teknik är 10 till 100 gånger mer känslig än dagens teknik och kan upptäcka en mutation på […]
Rarity support Elicera Therapeutics in cutting edge CAR-T therapy study
On behalf of the sponsor, Elicera Therapeutics, Rarity is supporting the ELC301 translational study with analysis of the vector copy number (VCN) of integrated retroviral vectors in engineered Human T-cells. “The assay from Rarity shows similar or better CV than current available ddPCR assays, and a much more cost efficient alternative. Based on the sensitivity […]
Poster presented at EACR Liquid Biopsy
Poster presentation by Lei Chen,PhD at the European Association for Cancer Research (EACR) conference on Liquid Biopsy in Bergamo, Italy. The poster focused on the superRCA single tube assay workflow, the assay sensitivity and precision, followed by multiplex example from colorectal patients. “Great conference and lots of attention and positive response, also amazing to see […]
Rarity receives ‘Attractive Innovation Project Award 2021’
The award from Uppsala University Innovation goes to startup companies that has successfully attracted external funding and made technological advancements. ‘Rewarded for significant efforts and progress on the road from idea to innovation’ Due to the pandemic and national restrictions, the 2021 award ceremony and announcement was delayed, but this week the reward was finally […]
Rarity receives prestigious SweLife grant together with SciLifeLabs, Karolinska Institutet, and Uppsala University Hospital
Rarity has been awarded a grant from Swelife and Medtech4Health – Collaboration project for better health, fall 2021. The project is a partner project with SciLifeLabs, Karolinska Institutet and Uppsala University Hospital. The aim of the project is to implement SuperRCA for precision diagnostics & relapse detection for Acute Myeloid Leukemia and Myelodysplastic syndrome – ultimately […]
Hanna Kocken joins Rarity as Head of Quality and Regulatory
The strategic recruitment extends the company’s management team and enhances their ability to execute on the mission: to deliver high quality products for scientific and clinical applications. Hanna brings extensive experience from the In Vitro Diagnostics industry, most recently from a senior position at Thermo Fisher Scientific. Her substantial knowledge in quality and regulatory compliance […]
Rarity IDH1/IDH2 Panel for Acute Myeloid Leukemia
The SuperRCA technology was first developed together with hematologists to aid in ultrasensitive detection of rare mutations in leukemic variants, such as Acute Myeloid Leukemia (AML). We are therefore happy to announce that our first version of the Rarity AML panel is now available for research service testing, covering the relevant mutations for targeted treatment […]